These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

606 related items for PubMed ID: 14731052

  • 1. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA, Foster RH.
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [Abstract] [Full Text] [Related]

  • 2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [Abstract] [Full Text] [Related]

  • 3. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G, Jönsson L, Young A, Eberhardt K.
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [Abstract] [Full Text] [Related]

  • 4. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis.
    Wong JB, Singh G, Kavanaugh A.
    Am J Med; 2002 Oct 01; 113(5):400-8. PubMed ID: 12401535
    [Abstract] [Full Text] [Related]

  • 5. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR, Hay J.
    Pharmacoeconomics; 2006 Oct 01; 24(12):1221-32. PubMed ID: 17129076
    [Abstract] [Full Text] [Related]

  • 6. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2004 Oct 01; 22(16):1071-95. PubMed ID: 15524495
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.
    Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, Geborek P, Neovius M.
    Ann Rheum Dis; 2015 Jun 01; 74(6):1094-101. PubMed ID: 24737786
    [Abstract] [Full Text] [Related]

  • 8. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV, Chiou CF, Dubois RW.
    J Manag Care Pharm; 2006 Sep 01; 12(7):555-69. PubMed ID: 16981801
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A, Cifaldi MA, Segurado OG, Weisman MH.
    J Rheumatol; 2009 Jan 01; 36(1):16-26. PubMed ID: 19012363
    [Abstract] [Full Text] [Related]

  • 10. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.
    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.
    Health Technol Assess; 2006 Sep 01; 10(31):iii-iv, xiii-xvi, 1-239. PubMed ID: 16948890
    [Abstract] [Full Text] [Related]

  • 11. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
    Barbieri M, Wong JB, Drummond M.
    Pharmacoeconomics; 2005 Sep 01; 23(6):607-18. PubMed ID: 15960556
    [Abstract] [Full Text] [Related]

  • 12. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM, Perry CM.
    BioDrugs; 2002 Sep 01; 16(2):111-48. PubMed ID: 11985485
    [Abstract] [Full Text] [Related]

  • 13. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ, Brennan A, Ghatnekar O.
    Ann Rheum Dis; 2005 Jul 01; 64(7):995-1002. PubMed ID: 15550533
    [Abstract] [Full Text] [Related]

  • 14. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep 01; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 15. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.
    Z Rheumatol; 2004 Feb 01; 63(1):59-75. PubMed ID: 14991279
    [Abstract] [Full Text] [Related]

  • 16. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M, Nakamura I, Ito K, Tanaka H, Ohta H, Kobayashi M, Tachihara A, Nagashima M, Yoshino S, Nakajima A.
    Mod Rheumatol; 2006 Feb 01; 16(2):77-84. PubMed ID: 16633926
    [Abstract] [Full Text] [Related]

  • 17. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W, Jobanputra P, Barton P, Burls A.
    Health Technol Assess; 2004 May 01; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [Abstract] [Full Text] [Related]

  • 18. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A, Boland A, Hockenhull J, Fleeman N, Greenhalgh J, Dundar Y, Proudlove C, Kennedy T, Moots R, Williamson P, Dickson R.
    Health Technol Assess; 2009 Sep 01; 13 Suppl 2():23-9. PubMed ID: 19804686
    [Abstract] [Full Text] [Related]

  • 19. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G, Eberhardt K, Geborek P.
    Ann Rheum Dis; 2004 Jan 01; 63(1):4-10. PubMed ID: 14672883
    [Abstract] [Full Text] [Related]

  • 20. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.
    Rheumatology (Oxford); 2007 Aug 01; 46(8):1345-54. PubMed ID: 17562686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.